65 results on '"treprostinil"'
Search Results
2. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
3. Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-OLE)
4. Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
5. Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)
6. Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso (BREEZE)
7. Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)
8. Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
9. Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin (EVOLVE)
10. Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
11. Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
12. FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
13. Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) (TRIUMPH)
14. A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
15. Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
16. TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) (TRUST-2)
17. Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
18. Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (DISTOL-1)
19. Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) (PERFECT OLE)
20. A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) (PERFECT)
21. EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
22. ADAPT - A Patient Registry of the Real-world Use of Orenitram® (ADAPT)
23. An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
24. Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
25. An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
26. An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension (FREEDOM-EXT)
27. Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH (PRN)
28. Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
29. Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF
30. Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy (FREEDOM-EV)
31. Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
32. Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
33. Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) (RAPID)
34. FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
35. Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
36. An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
37. Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
38. Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
39. Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
40. A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
41. A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
42. Remodulin® to Oral Treprostinil Transition
43. Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
44. Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies (Aspire)
45. Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers (TDE-PH-125)
46. Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers
47. Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension (TRUST-1)
48. Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
49. Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
50. A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.